Zivo Bioscience Inc. Announces New Clinical Study to Advance Immune-Enhancing Compounds in Poultry Market

Reuters06-20

Zivo Bioscience Inc. Announces New Clinical Study to Advance Immune-Enhancing Compounds in Poultry Market

ZIVO Bioscience Inc. has announced two new clinical studies fully funded by a collaborating company. The studies aim to evaluate several ZIVO product candidates for their potential to enhance the immune response following immunization, reduce the time between immunization and the onset of protective immunity, and mitigate the immunosuppressive effects of diseases in poultry. The first study, lasting 42 days, will focus on coccidiosis, a parasitic disease affecting poultry worldwide, and will assess the compound's performance when co-administered with a collaborator's vaccine. The second study will explore ZIVO's compounds against a viral poultry disease characterized by rapid onset and high mortality rates. This study follows previous data showing reduced severity of low-pathogenic avian influenza in treated birds. Results from these trials have not yet been presented and are intended to support regulatory approval and validate commercial applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zivo Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250620564330) on June 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2544247801?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-20 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544247801","market":"fut","top_or_hot":-1,"title":"Zivo Bioscience Inc. Announces New Clinical Study to Advance Immune-Enhancing Compounds in Poultry Market","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zivo Bioscience Inc. Announces New Clinical Study to Advance Immune-Enhancing Compounds in Poultry Market\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ZIVO Bioscience Inc. has announced two new clinical studies fully funded by a collaborating company. The studies aim to evaluate several ZIVO product candidates for their potential to enhance the immune response following immunization, reduce the time between immunization and the onset of protective immunity, and mitigate the immunosuppressive effects of diseases in poultry. The first study, lasting 42 days, will focus on coccidiosis, a parasitic disease affecting poultry worldwide, and will assess the compound's performance when co-administered with a collaborator's vaccine. The second study will explore ZIVO's compounds against a viral poultry disease characterized by rapid onset and high mortality rates. This study follows previous data showing reduced severity of low-pathogenic avian influenza in treated birds. Results from these trials have not yet been presented and are intended to support regulatory approval and validate commercial applications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zivo Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250620564330) on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zivo Bioscience Inc. Announces New Clinical Study to Advance Immune-Enhancing Compounds in Poultry Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZivo Bioscience Inc. Announces New Clinical Study to Advance Immune-Enhancing Compounds in Poultry Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-20 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zivo Bioscience Inc. Announces New Clinical Study to Advance Immune-Enhancing Compounds in Poultry Market\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ZIVO Bioscience Inc. has announced two new clinical studies fully funded by a collaborating company. The studies aim to evaluate several ZIVO product candidates for their potential to enhance the immune response following immunization, reduce the time between immunization and the onset of protective immunity, and mitigate the immunosuppressive effects of diseases in poultry. The first study, lasting 42 days, will focus on coccidiosis, a parasitic disease affecting poultry worldwide, and will assess the compound's performance when co-administered with a collaborator's vaccine. The second study will explore ZIVO's compounds against a viral poultry disease characterized by rapid onset and high mortality rates. This study follows previous data showing reduced severity of low-pathogenic avian influenza in treated birds. Results from these trials have not yet been presented and are intended to support regulatory approval and validate commercial applications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zivo Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250620564330) on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"个人用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDLcbqrHt:1","article_id":"2544247801","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544247801","pubTimestamp":1750420826,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ZIVO Bioscience Inc. has announced two new clinical studies fully funded by a collaborating company. The studies aim to evaluate several ZIVO product candidates for their potential to enhance the immune response following immunization, reduce the time between immunization and the onset of protective immunity, and mitigate the immunosuppressive effects of diseases in poultry. The first study, lasting 42 days, will focus on coccidiosis, a parasitic disease affecting poultry worldwide, and will assess the compound's performance when co-administered with a collaborator's vaccine. The second study will explore ZIVO's compounds against a viral poultry disease characterized by rapid onset and high mortality rates. This study follows previous data showing reduced severity of low-pathogenic avian influenza in treated birds. Results from these trials have not yet been presented and are intended to support regulatory approval and validate commercial applications.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4183":"个人用品","ZIVO":"Zivo Bioscience, Inc."},"translate_title":"Zivo Bioscience Inc.宣布新的临床研究，以推进家禽市场的免疫增强化合物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZIVO":0.9},"content_text":"Zivo Bioscience Inc. Announces New Clinical Study to Advance Immune-Enhancing Compounds in Poultry Market\n    \n\n        ZIVO Bioscience Inc. has announced two new clinical studies fully funded by a collaborating company. The studies aim to evaluate several ZIVO product candidates for their potential to enhance the immune response following immunization, reduce the time between immunization and the onset of protective immunity, and mitigate the immunosuppressive effects of diseases in poultry. The first study, lasting 42 days, will focus on coccidiosis, a parasitic disease affecting poultry worldwide, and will assess the compound's performance when co-administered with a collaborator's vaccine. The second study will explore ZIVO's compounds against a viral poultry disease characterized by rapid onset and high mortality rates. This study follows previous data showing reduced severity of low-pathogenic avian influenza in treated birds. Results from these trials have not yet been presented and are intended to support regulatory approval and validate commercial applications.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zivo Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250620564330) on June 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2544247801","isCrawlerRequest":true}